Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) EV/Sales
As of 16 October 2026, Amylyx Pharmaceuticals, Inc. (AMLX) trades at a EV/Sales of 30.7×. Over the past ten years it has ranged from −0.7× (June 2024) to 47.6× (August 2026); the current reading is higher than 96% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.9× | (43.51%) |
| FY2023 | 1.7× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 0.9× | — |
| Sep 2024 | −0.1× | — |
| Jun 2024 | −0.6× | — |
| Mar 2024 | −0.5× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| PRGO Perrigo Company plc compare | 1.3× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| LQDA Liquidia Corporation compare | 6.5× |
| ALVO Alvotech compare | 9.0× |
| AMLX Amylyx Pharmaceuticals, Inc. | 30.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)